[go: up one dir, main page]

PT3037424T - Novo composto substituído com quinolina - Google Patents

Novo composto substituído com quinolina

Info

Publication number
PT3037424T
PT3037424T PT148372105T PT14837210T PT3037424T PT 3037424 T PT3037424 T PT 3037424T PT 148372105 T PT148372105 T PT 148372105T PT 14837210 T PT14837210 T PT 14837210T PT 3037424 T PT3037424 T PT 3037424T
Authority
PT
Portugal
Prior art keywords
substituted compound
novel quinoline
quinoline
novel
substituted
Prior art date
Application number
PT148372105T
Other languages
English (en)
Inventor
Nonoshita Katsumasa
Uno Takao
Shimamura Tadashi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of PT3037424T publication Critical patent/PT3037424T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PT148372105T 2013-08-22 2014-08-22 Novo composto substituído com quinolina PT3037424T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013172746 2013-08-22

Publications (1)

Publication Number Publication Date
PT3037424T true PT3037424T (pt) 2017-12-18

Family

ID=52483707

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148372105T PT3037424T (pt) 2013-08-22 2014-08-22 Novo composto substituído com quinolina

Country Status (22)

Country Link
US (2) US9650386B2 (pt)
EP (1) EP3037424B1 (pt)
JP (1) JP6161705B2 (pt)
KR (1) KR101906688B1 (pt)
CN (1) CN105683195B (pt)
AU (1) AU2014309788B2 (pt)
BR (1) BR112016003247B1 (pt)
CA (1) CA2922077C (pt)
DK (1) DK3037424T3 (pt)
ES (1) ES2656712T3 (pt)
HK (1) HK1222393A1 (pt)
HU (1) HUE034807T2 (pt)
MX (1) MX370808B (pt)
MY (1) MY182891A (pt)
NO (1) NO3037424T3 (pt)
PH (1) PH12016500225A1 (pt)
PL (1) PL3037424T3 (pt)
PT (1) PT3037424T (pt)
RU (1) RU2689158C2 (pt)
SG (1) SG11201600759XA (pt)
TW (1) TWI603971B (pt)
WO (1) WO2015025936A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3037424T (pt) * 2013-08-22 2017-12-18 Taiho Pharmaceutical Co Ltd Novo composto substituído com quinolina
JOP20190073A1 (ar) * 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
TWI782931B (zh) * 2016-11-17 2022-11-11 美國德州系統大學評議委員會 具有對抗帶有egfr或her2外顯子20突變之癌細胞之抗腫瘤活性的化合物
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
FR3068971B1 (fr) * 2017-07-12 2019-08-30 Protneteomix Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer
TWI838345B (zh) * 2017-09-01 2024-04-11 日商大鵬藥品工業股份有限公司 外顯子18及/或外顯子21突變型egfr之選擇性抑制劑
CN113423403B (zh) * 2018-12-28 2025-02-18 大鹏药品工业株式会社 对l718和/或l792突变型治疗有抗性的egfr抑制剂
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR102318875B1 (ko) 2019-03-19 2021-11-01 보로노이 주식회사 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
CN115181104A (zh) * 2019-09-29 2022-10-14 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
AU2022257621A1 (en) 2021-04-13 2023-11-23 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
TW202317126A (zh) 2021-06-15 2023-05-01 美商建南德克公司 Egfr抑制劑和perk活化劑組合療法
CN115707704B (zh) * 2021-08-20 2024-09-13 广东医诺维申生物技术有限公司 氘代稠合三环类化合物及其组合物和用途
WO2024121805A1 (en) 2022-12-08 2024-06-13 Assia Chemical Industries Ltd. Solid state forms of zipalertinib and process for preparation thereof
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
WO2024248083A1 (ja) * 2023-05-31 2024-12-05 大鵬薬品工業株式会社 キノリン置換化合物の結晶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
CA2601766A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
US8779142B2 (en) 2009-07-10 2014-07-15 Taiho Pharmaceutical Co., Ltd. Azabicyclo compound and salt thereof
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2662357B1 (en) 2011-01-07 2016-08-03 Taiho Pharmaceutical Co., Ltd. Bicyclic compounds or salts thereof for use in the treatment of cancer
EP2762476A4 (en) 2011-09-30 2015-03-25 Taiho Pharmaceutical Co Ltd 1,2,4-triazine-6-carboxamide derivative
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
WO2013125709A1 (ja) * 2012-02-23 2013-08-29 大鵬薬品工業株式会社 キノリルピロロピリミジル縮合環化合物又はその塩
WO2014129596A1 (ja) 2013-02-22 2014-08-28 大鵬薬品工業株式会社 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物
PT3037424T (pt) * 2013-08-22 2017-12-18 Taiho Pharmaceutical Co Ltd Novo composto substituído com quinolina

Also Published As

Publication number Publication date
PL3037424T3 (pl) 2018-03-30
RU2689158C2 (ru) 2019-05-24
CN105683195B (zh) 2017-11-10
TWI603971B (zh) 2017-11-01
RU2016110096A (ru) 2017-09-27
EP3037424A4 (en) 2017-01-25
WO2015025936A1 (ja) 2015-02-26
US9650386B2 (en) 2017-05-16
CA2922077A1 (en) 2015-02-26
BR112016003247A2 (pt) 2017-08-01
JP6161705B2 (ja) 2017-07-12
US9758526B2 (en) 2017-09-12
AU2014309788B2 (en) 2017-02-16
MY182891A (en) 2021-02-05
US20170101414A1 (en) 2017-04-13
RU2016110096A3 (pt) 2018-06-18
EP3037424A1 (en) 2016-06-29
PH12016500225B1 (en) 2016-05-02
PH12016500225A1 (en) 2016-05-02
DK3037424T3 (en) 2017-12-11
ES2656712T3 (es) 2018-02-28
US20160194332A1 (en) 2016-07-07
SG11201600759XA (en) 2016-03-30
NO3037424T3 (pt) 2018-04-07
MX370808B (es) 2020-01-07
AU2014309788A1 (en) 2016-03-10
KR20160043114A (ko) 2016-04-20
CN105683195A (zh) 2016-06-15
TW201542547A (zh) 2015-11-16
HUE034807T2 (en) 2018-02-28
JPWO2015025936A1 (ja) 2017-03-02
HK1222393A1 (zh) 2017-06-30
EP3037424B1 (en) 2017-11-08
MX2016002125A (es) 2016-06-28
KR101906688B1 (ko) 2018-10-10
CA2922077C (en) 2018-06-26
RU2019114688A (ru) 2020-07-29
BR112016003247B1 (pt) 2022-05-10

Similar Documents

Publication Publication Date Title
IL249517A0 (en) A compound that inhibits trk
HK1224312A1 (zh) 新型化合物
HK1222393A1 (zh) 新的喹啉取代的化合物
GB201311910D0 (en) Novel Compounds
GB201311888D0 (en) Novel compounds
GB201302368D0 (en) Compound
HK1219100A1 (zh) 吡啶基吡唑並喹啉化合物
GB201314926D0 (en) Novel Compounds
EP2970113A4 (en) NOVEL CONNECTIONS
GB201316762D0 (en) Novel compounds
GB201307331D0 (en) Compound
GB201408643D0 (en) Compound
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201321972D0 (en) Novel compounds
GB201321975D0 (en) Novel compounds
GB201321811D0 (en) Novel compounds
GB201301585D0 (en) Compound
GB201316100D0 (en) Novel compounds
GB201314477D0 (en) Novel compounds
GB201314309D0 (en) Novel Compounds
GB201313933D0 (en) Novel compounds
GB201310456D0 (en) Novel Compounds